A miRNA-483-5p inhibitor drug and its application in medicine for treating osteoarthritis

A technology of osteoarthritis and inhibitors, applied in the field of biopharmaceuticals, can solve problems such as untreatable and preventable, and achieve the effect of delaying the progress of the disease

Active Publication Date: 2019-12-03
广州南方医大科技园有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The current treatment methods can only alleviate the symptoms of bone and joint diseases to a limited extent, and cannot treat and prevent them from the physiological structure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A miRNA-483-5p inhibitor drug and its application in medicine for treating osteoarthritis
  • A miRNA-483-5p inhibitor drug and its application in medicine for treating osteoarthritis
  • A miRNA-483-5p inhibitor drug and its application in medicine for treating osteoarthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The establishment of embodiment 1 osteoarthritis model

[0029] In this experiment, destabilization of the medial meniscus (DMM, destabilization of the medial meniscus) method was chosen as the experimental osteoarthritis mouse model. Wild-type male C57Bl / 6J and TG483 mice aged 8-10 weeks were selected for modeling. After the internal collateral ligament and anterior cruciate ligament were resected in the right knee joint of the mice in the experimental group, the internal meniscus was removed. In the sham operation group, only the skin incision of the right knee joint was performed. Typically, mice were sacrificed five weeks after surgery, and joint specimens were removed for subsequent testing.

Embodiment 2

[0030] Embodiment 2 intra-articular injection administration

[0031] A 33-gauge and a micro-syringe were used for intra-articular injection, and the virus titer injected in the administration group was 1×10 9 TU / ml, the concentration of antagomiR-483-5p (SEQ ID No.1) was 250 μM, the volume of each injection was 10 μl, and the injection was divided into two injections on the 7th day and the 14th day after operation.

Embodiment 3

[0032] The fixation of embodiment 3 tissue and the preparation of paraffin section

[0033] ①The complete right knee joint tissue was stripped and fixed in 4% paraformaldehyde fixative solution on a shaker at 4°C for 20-22 hours;

[0034] ② Rinse the fixed tissue with PBS for 5 minutes each time, twice in total. Then decalcification treatment is carried out, and the decalcification solution is 0.5MEDTA, pH 7.4. The decalcification solution was replaced every 2-3 days, and the total decalcification time was three weeks.

[0035] ③Automatic dehydrator for dehydration, transparency and wax dipping. Ethanol solution step by step dehydration, the specific program is: 50% ethanol solution, 2 hours; 70% ethanol solution, 2 hours; 80% ethanol solution, 2 hours; 95% ethanol solution, 2 hours; 100% ethanol 1, 1 hour; 100% ethanol II, 1 hour;

[0036]④ Transparent, that is, the ethanol solution is replaced by xylene. The specific procedure is: xylene I, 30 minutes; xylene II, 30 minu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an miRNA-483-5p inhibitor and an application thereof in treating osteoarthritis. Specifically, the invention discloses an application of the miRNA-483-5p inhibitor in preparing medicines for treating the osteoarthritis, wherein the miRNA-483-5p inhibitor is selected from a nucleotide sequence, which can achieve a specific miRNA-483-5p inhibiting effect, in cells.

Description

technical field [0001] The invention relates to the field of biopharmaceuticals, in particular to the use of a miRNA-483-5p inhibitor in the preparation of medicines for treating osteoarthritis. Background technique [0002] Osteoarthritis (OA, osteoarthritis) is a degenerative disease, which is caused by many factors such as aging, obesity, strain, trauma, congenital abnormalities of joints, joint deformities and other factors. Sexual hyperplasia, also known as osteoarthritis, degenerative arthritis, senile arthritis, hypertrophic arthritis, etc. Clinical manifestations include slowly developing joint pain, tenderness, stiffness, joint swelling, limited mobility, and joint deformity. [0003] The treatment for bone and joint diseases is mainly to reduce the load on the joints and excessive large-scale activities, so as to delay the progress of the disease. Obese patients should lose weight to reduce the load on the joints. When the lower extremity joints have lesions, cr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/7105A61K48/00A61P19/02A61P29/00
CPCA61K9/0019A61K31/7105A61K45/00
Inventor 白晓春王华张海严孙秋怡蔡道章
Owner 广州南方医大科技园有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap